Effects of systemic inflammation on relapse in early breast cancer.
Nicholas P McAndrewLisa N BottalicoClementina MesarosIan A BlairPatricia Y TsaoJennifer M RosadoTapan GangulySarah J SongPhyllis A GimottyJun J MaoAngela M DeMichelePublished in: NPJ breast cancer (2021)
Chronic inflammation has been a proposed mechanism of resistance to aromatase inhibitors in breast cancer. Stratifying by HER2 status, a matched case-control study from the Wellness After Breast Cancer-II cohort was performed to assess whether or not elevated serum inflammatory biomarkers (C-Reactive protein [CRP], interleukin-6 [IL-6], and serum amyloid A [SAA]) and/or the presence of a high-risk IL-6 promoter genotype were associated with recurrence of hormone receptor positive (HR+) early breast cancer. Estrogen levels were also measured and correlated with biomarkers and disease outcomes. CRP and SAA were significantly associated with an increased risk of recurrence in the HR+/HER2- group, but not the HR+/HER2+ group. Mean serum estrogen levels were non-significantly elevated in patients who relapsed vs. non-relapsed patients. Surprisingly, high-risk IL-6 promoter polymorphisms were strongly associated with HER2+ breast cancer relapse, which has potential therapeutic implications, as elevated intracellular IL-6 has been associated with trastuzumab resistance in pre-clinical models.
Keyphrases
- early breast cancer
- free survival
- acute lymphoblastic leukemia
- acute myeloid leukemia
- dna methylation
- gene expression
- oxidative stress
- diffuse large b cell lymphoma
- multiple myeloma
- transcription factor
- newly diagnosed
- ejection fraction
- hodgkin lymphoma
- estrogen receptor
- prognostic factors
- type diabetes
- skeletal muscle
- metabolic syndrome
- tyrosine kinase
- insulin resistance
- metastatic breast cancer